The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

Weil, Gotshal & Manges LLP

Work +1 212 310 8000
Fax +1 212 310 8007

Jeffrey Osterman

Work +1 212 310 8155
Weil, Gotshal & Manges LLP


Jeffrey Osterman concentrates on matters with deep commercial or technical complexity. He has experience with pure patent licensing, technology transfer, outsourcing, pharmaceutical collaboration and technology integration. He has advised Verizon in its acquisition of over-the-top cable television technology from Intel, Lenovo in its acquisition of Motorola Mobility from Google and Sanofi in its worldwide exclusive licensing agreement with MannKind Corporation to develop and commercialize Afrezza (insulin human) Inhalation Powder. He has lectured on IP and technology throughout the US and on US IP and contract law in Japan.


Cornell University (BA, 1992); Harvard Law School (JD, 1995).

United States: Industry focus

Healthcare: life sciences

Within: Healthcare: life sciences

The ‘thorough’ and ‘strong’ group at Weil, Gotshal & Manges LLP advises on the full gamut of corporate and litigation matters for clients in the life sciences arena, including antitrust and IP issues. Silicon Valley-based co-head Edward Reines successfully represented Stanford University in an appeal arising from an inventorship dispute with the Chinese University of Hong Kong regarding a revolutionary test for Down’s syndrome. ‘Extremely organized’ patent litigation partner Elizabeth Weiswasser, who has a ‘solid understanding of scientific issues’, has been representing Acorda Therapeutics in the company’s appeal to the Federal Circuit regarding a patent infringement judgment involving its Ampyra drug. IP partner Jeffrey Osterman and private equity partner Christopher Machera led advice to National Surgical Hospitals on its $760m acquisition by Surgery Partners. The group is also headed by Michael Epstein. Named partners are based in New York unless otherwise stated.

[back to top]

United States: Intellectual property

Patents: licensing

Within: Patents: licensing

Weil, Gotshal & Manges LLP’s key area of expertise is technology transactions, but the team is also adept at assisting life sciences clients. On the corporate transactional side, the group covers licences in relation to mergers and acquisitions, joint ventures, and strategic alliances, while the non-transactional practice includes research and development agreements as well as e-commerce contracts, outsourcing transactions and professional service agreements. The firm is present in New York, where practice head Michael Epstein, Jeffrey Osterman and Charan Sandhu are based, and on the West Coast; here Karen Ballack is the main contact in Silicon Valley after John Brockland left for Hogan Lovells US LLP. Despite Brockland’s departure the group handles a large number of high-profile matters, such as advising Sanofi on the licensing aspects of its $25bn agreement with Boehringer Ingelheim through which the client swapped its animal health business Merial for Boehringer’s consumer healthcare business. General Electric, Signet Jewelers and Eli Lilly are other key clients.

[back to top]

United States: Media, technology and telecoms

Technology: transactions

Within: Technology: transactions

Weil, Gotshal & Manges LLP is regularly engaged in sophisticated transactions, including technology acquisitions and dispositions, joint ventures and strategic alliances, as well as research and development (R&D) collaborations, licensing agreements, outsourcing transactions and e-commerce agreements. New York-based global technology and IP transactions head Michael Epstein acted for inVentiv Health in the technology and IP aspects of its $4.6bn merger with INC Research Holdings; Charan Sandhu advised the transaction committee of the board of directors of Reynolds American (Reynolds) on the technology and IP aspects of its $60.6bn sale to British American Tobacco (BAT) of the 57.8% of Reynolds’ stock that BAT did not already own; and Jeffrey Osterman advised French multinational pharmaceutical company Sanofi on the technology and IP aspects of the $25bn exchange of its animal health business for the consumer healthcare business of Boehringer Ingelheim. Silicon Valley-based Karen Ballack is also highly rated. Richard Climan, John Brockland, Max Scott, Keith Flaum, Jane Ross, and Christopher Moore joined Hogan Lovells US LLP.

[back to top]

Back to index

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to